Navigation Links
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Date:2/29/2008

one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that PRISTIQ will be commercially successful in the highly competitive market for antidepressants in the United States, or that PRISTIQ will be approved in the future for other indications (including treatment of vasomotor symptoms associated with menopause) and/or in other countries. Other risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products (including future regulatory action regarding our other pending applications for desvenlafaxine for the treatment of major depressive disorder and the treatment of vasomotor symptoms, as to which no assurance can be given); government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
2. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
3. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
4. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
6. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
9. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
10. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Human Albumin Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth study ... industry. The report provides a basic overview ... chain structure. The human albumin market analysis is provided ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
(Date:9/18/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... underwritten offerings of 10,000,000 shares of its Common Stock ... share, for expected gross proceeds of $20 million and ... at a price to the public of $2,000.00 per ... share of Series A Convertible Preferred Stock is non-voting ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
...   Sigma-Aldrich Corporation (NASDAQ: ... announced it has signed an agreement to acquire BioReliance Holdings, ... Avista Capital Partners for $350 million in cash.  The acquisition ... is expected to close in the first quarter of 2012.  ...
... According to a new market research report, ... , published by MarketsandMarkets ( http://www.marketsandmarkets.com ), global seed ... protection market. This growth is fueled by government encouragement ... This growth is particularly higher in geographies such as ...
... GENEVA, Jan. 9, 2012   Selexis SA announced ... Vice President of Strategic and Market Development. ... CEO, Dr. Igor Fisch and will be responsible for ... biologics and difficult-to-express protein markets. ...
Cached Biology Technology:Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 2MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016 3Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development 2
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... transcription the process inside the nucleus of cells by ... a large, ever-changing multiprotein complex is enlisted to assist ... an exquisitely choreographed dance, each step in the process has ... to be accurate and useful in subsequent events. These ...
... discovery by Canada-U.S. biophysicists will improve the understanding of ion ... which when they malfunction can cause genetic illnesses that attack ... As reported in the current issue of the Proceedings ... researchers from the Universit de Montral and the University of ...
... we maximise the value and use of epidemiological ... the theme of a conference being held on ... Co-organised by PHOEBE (Promoting Harmonisation of Epidemiological Biobanks), ... (Biobanking and Biomolecular Resources Research Infrastructure), the conference ...
Cached Biology News:CSHL scientists discover new way in which ubiquitin modifies transcriptional machinery 2Researchers advance knowledge of little 'nano-machines' in our body 2Harmonizing Biobank Research Conference in 2009 2Harmonizing Biobank Research Conference in 2009 3
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Biology Products: